Quantcast

Latest Memorial Sloan–Kettering Cancer Center Stories

2010-08-26 14:03:25

A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine. "Metastatic melanoma is a very challenging disease to treat and there have been no significant...

2010-06-26 04:01:20

A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This...

2010-04-21 06:30:00

NEW YORK, April 21 /PRNewswire/ -- The Kristen Ann Carr Fund has awarded a grant to Jonathan Lewis, MD, PhD, Chief Executive Officer and Chief Medical Officer of ZIOPHARM Oncology, Inc., which will fund translational work at the Memorial Sloan-Kettering Cancer Center and the Albert Einstein College of Medicine in New York City, for the development of a novel treatment for pediatric sarcoma. The competitive grant was established to honor the 70th birthday of Murray F. Brennan, MD, Chairman...

2010-04-15 08:25:10

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its poor prognosis and limited treatment options. The research, led by investigators at Memorial Sloan-Kettering Cancer Center, appears early online and in an upcoming edition of The Lancet. According to the...

2010-04-07 06:50:00

PHILADELPHIA, April 7 /PRNewswire/ -- The Sidney Kimmel Foundation for Cancer Research has selected fifteen scientists from across the United States to receive two-year grants under the Foundation's on-going Kimmel Scholar program. A total of 187 talented cancer researchers have been provided with grant money since the Foundation's inception with each receiving a $200,000 award to further a specific cancer research project. The Kimmel Scholar Awards were created in 1997 to advance the...

2010-04-05 17:13:00

HACKENSACK, N.J., April 5 /PRNewswire/ -- John Theurer Cancer Center at Hackensack University Medical Center will bring together top neuro-oncologists from around the country for a symposium to address new treatment updates and review management of complex cases across a broad array of neuro-oncology specialties. The Sixth Annual Neuro-Oncology Symposium: Update of New Guidelines in Neuro-Oncology will take place on Friday, April 9. The program will feature neuro-oncology experts from...

2010-03-16 09:44:44

Nearly half of colon cancer patients will develop liver metastases; the majority will not be candidates for surgery"”interventional radiology treatment destroys cancer locally, extends life Approximately half of Americans living with colorectal cancer will develop liver metastases at some point during the course of their disease. Radiofrequency ablation, a minimally invasive treatment that applies heat directly in the tumor causing cancer cell death with minimal associated injury to the...

2010-03-11 09:33:03

A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels. Ethan Basch, MD, outcomes researcher and medical oncologist at Memorial Sloan-Kettering Cancer Center, recommends that fundamental change is necessary in order to improve the process of...

2010-03-02 09:00:00

BETHPAGE, N.Y., March 2 /PRNewswire/ -- The Lustgarten Foundation announced today that it has formed a national pancreatic cancer research consortium, a collaborative effort involving six world-renowned medical institutions to advance the most promising research initiatives aimed at finding a cure for pancreatic cancer. Named the Pancreatic Cancer Research Consortium (PCRC), The Lustgarten Foundation will provide an initial $10 million in grants this year for research in the prevention,...

2010-01-19 07:00:00

Annual Fundraising Event To Be Held At Roseland Ballroom In New York City On April 18(th) NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- The T.J. Martell Foundation announced today that it will honor the Grammy-nominated and multi-platinum selling music artists, Jonas Brothers, along with their management at the 11(th) Annual T.J. Martell Foundation Family Day fundraising event. The celebration will be held on Sunday, April 18(th), 2010 at the legendary Roseland Ballroom, located at 239...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related